FDA Clears Canon’s Alphenix/Evolve Edition With αEvolve Imaging

December 1, 2025—Canon Medical Systems USA announced FDA 510(k) clearance for its latest interventional cardiology imaging system, the Alphenix/Evolve Edition with αEvolve (alpha Evolve) imaging. The Alphenix/Evolve Edition is now commercially available in the United States, advised the company.

Canon noted that it showcased the Alphenix/Evolve Edition at TCT 2025 scientific symposium in October.

According to Canon, the Alphenix/Evolve Edition is designed to enhance fluoroscopic imaging quality during routine and complex percutaneous coronary interventions (PCI) with a wide range of solutions for the interventional cardiology suite. Under the αEvolve technology umbrella, which includes artificial intelligence solutions, these tools provide real-time support for diagnostic and therapeutic decisions without disrupting the procedural flow. αEvolve imaging features include noise reduction and multifrequency processing. Its dynamic device stabilizer detects balloon markers in real-time, magnifies, and stabilizes the image on a separate screen to assist with stent visualization and assessment during complex PCI procedures.

The αEvolve technology is currently available for 6-inch and 8-inch field of view 12- X 12-inch high-definition flat panel detectors, depending on system configuration, stated Canon.